Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
14 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to UroGen Pharma Ltd.’s names, not what it holds today.
Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 1 in 2024 and 1 in 2023
Applications published
24
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Medical technology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
UroGen Pharma Ltd. its own name
IL, as the owner printed on each patent
14 granted
9 publishedUroGen Pharma Ltd. its own name
named as the applicant on its applications, in IL
0 granted
15 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Oct 14, 2025 | 12,440,568 | Material and method for treating internal cavities | Pharmaceuticals | UroGen Pharma Ltd. |
| Jun 24, 2025 | 12,336,979 | Material and method for treating cancer | Pharmaceuticals | UroGen Pharma Ltd. |
| Apr 8, 2025 | 12,268,745 | Material and method for treating internal cavities | Pharmaceuticals | UroGen Pharma Ltd. |
| Apr 1, 2025 | 12,263,245 | Immunomodulating treatments of body cavities | Pharmaceuticals | UroGen Pharma Ltd. |
| Dec 24, 2024 | 12,171,747 | Material and method for treating cancer | Pharmaceuticals | UroGen Pharma Ltd. |
| Feb 14, 2023 | 11,576,744 | Thermosensitive bio-adhesive hydrogel for removal of ureteral and renal stones | Medical technology | UroGen Pharma Ltd. |
| May 4, 2021 | 10,994,109 | Connectable catheter | Medical technology | UroGen Pharma Ltd. |
| Sep 1, 2020 | 10,758,482 | Immunomodulating treatments of body cavities | Pharmaceuticals | UroGen Pharma Ltd. |
| Nov 12, 2019 | 10,471,150 | Material and method for treating internal cavities | Pharmaceuticals | UroGen Pharma Ltd. |
| Aug 7, 2018 | 10,039,832 | Material and method for treating internal cavities | Pharmaceuticals | UroGen Pharma Ltd. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 10, 2025 | 2025/0221929 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. |
| Jun 19, 2025 | 2025/0195665 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. · patent 12,440,568 granted from it |
| Jan 30, 2025 | 2025/0032409 | TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER WITH A THERMALLY GELLING PHARMACEUTICAL COMPOSITION CONTAINING MITOMYCIN | Pharmaceuticals | UroGen Pharma Ltd. |
| Nov 21, 2024 | 2024/0382420 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. · patent 12,263,245 granted from it |
| Sep 12, 2024 | 2024/0299550 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. · patent 12,268,745 granted from it |
| Apr 4, 2024 | 2024/0108603 | MATERIAL AND METHOD FOR TREATING CANCER | Pharmaceuticals | UroGen Pharma Ltd. · patent 12,171,747 granted from it |
| Mar 28, 2024 | 2024/0100019 | COMPOSITIONS COMPRISING A THERMOREVERSIBLE HYDROGEL, AND HAVING AN EXTENDED IN-USE PERIOD | Pharmaceuticals | UroGen Pharma Ltd. |
| Aug 3, 2023 | 2023/0241221 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. |
| Aug 3, 2023 | 2023/0241220 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. |
| Jul 27, 2023 | 2023/0233685 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES | Pharmaceuticals | UroGen Pharma Ltd. |
What it applied for, 2024 to 2025: Pharmaceuticals 7.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.